ASCO hypeI think ASCO will be the dealmaker catalyst.
Well... either we get a quick lucrative deal before ASCO or sometime after ASCO.
There are so many interested parties that participated in the Strategic Review. Everyone got a good look at TLN.
Time to decide for them.
Initial buyer is there and has been there ever since Dec. You can listen to last conf. call for that last statement. Management confirmed the bid as "serious" and from a "pharma" even dare to say that the pharma was "canadien".
AACR poster move is turning out to be brilliant.
At ASCO people are focussed on two subject IRessa revival and how Roche is desperately saying that they are "not in trouble" despite expensive acquisitions and new side effect to Tarceva.
KRAS has been a popular topic since the last 2 years and still remains dominant as there are now 5-6 available lab test for it.
Trial design for oncoloy is to aim for a targetted clinical trial. Find a specific subset of patient and just do the test on them.
Oncology market is 78 Billion and growing to tripple digit that even a small fraction of a cancer population can mean tripple digit millions sales.
4601 is an add-on drug. You can combine it with any EGFR inhibitor currently approved. 4601 will make it even work better. Go see the AACR poster.
Furthermor, 4601 gives you access to KRAS mutation populations and also many other known mutations. Market expansion.
4601 is a RAS regulator. It brings RAS and RHO back to normal level and then cascading effect resulting in end of proliferation, end of migration and cell death.
Need little compound with no side-effect.
A unique product. Pharmas want to own every type of drug c-Met inhibitors, RNA, Bi-par like product etc. Owning this unqiue drug sure will make their pipeline much stronger.
Also, when they buy TLN they 3 extra freebies for nothing : 232, Shigamabs and Caprion.
No brainer buy.
We have now a strong deal making catalyst : ASCO.
Once everybody sees what's out at ASCO, the DD is completed. The move will be made. Takeover of TLN.
I expect a volume to increase more and more as ASCO come closer and is passed.
On any day now, like I've been saying for months now, a deal will be announced.
Traders are selling small lots, there are very few shares available. We move much higher.
How to beat the generic threat? How to outsmart the competition? Get a mutant loving drug like 4601....
All the long time shareholders are ready to tender to an offer.... Management has the same interest to sell as shareholder as they will cash out big time on their options / warrants.
Everyone is a winner here.
Deal odds cannot get higher... It's nearing 100%.